248 related articles for article (PubMed ID: 21725200)
1. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
[TBL] [Abstract][Full Text] [Related]
3. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
6. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.
Vispé S; Deroide A; Davoine E; Desjobert C; Lestienne F; Fournier L; Novosad N; Bréand S; Besse J; Busato F; Tost J; De Vries L; Cussac D; Riond J; Arimondo PB
Oncotarget; 2015 Jun; 6(17):15265-82. PubMed ID: 25948775
[TBL] [Abstract][Full Text] [Related]
7. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
[TBL] [Abstract][Full Text] [Related]
8. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
9. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.
Vijayaraghavalu S; Labhasetwar V
Cancer Lett; 2013 Apr; 331(1):122-9. PubMed ID: 23305699
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2'-deoxycytidine and DNA-demethylation.
Patra SK; Bettuzzi S
Biochemistry (Mosc); 2009 Jun; 74(6):613-9. PubMed ID: 19645665
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.
Yan L; Nass SJ; Smith D; Nelson WG; Herman JG; Davidson NE
Cancer Biol Ther; 2003; 2(5):552-6. PubMed ID: 14614325
[TBL] [Abstract][Full Text] [Related]
13. Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
Ando T; Nishimura M; Oka Y
Leukemia; 2000 Nov; 14(11):1915-20. PubMed ID: 11069027
[TBL] [Abstract][Full Text] [Related]
14. Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation.
Biswal BK; Beyrouthy MJ; Hever-Jardine MP; Armstrong D; Tomlinson CR; Christensen BC; Marsit CJ; Spinella MJ
PLoS One; 2012; 7(12):e53003. PubMed ID: 23300844
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.
Hassler MR; Klisaroska A; Kollmann K; Steiner I; Bilban M; Schiefer AI; Sexl V; Egger G
Biochimie; 2012 Nov; 94(11):2297-307. PubMed ID: 22687603
[TBL] [Abstract][Full Text] [Related]
16. The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
Yan F; Shen N; Pang J; Molina JR; Yang P; Liu S
J Biol Chem; 2015 Jul; 290(30):18480-94. PubMed ID: 26085088
[TBL] [Abstract][Full Text] [Related]
17. Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.
Lin HY; Kuo YC; Weng YI; Lai IL; Huang TH; Lin SP; Niu DM; Chen CS
Prostate; 2012 Dec; 72(16):1767-78. PubMed ID: 22539223
[TBL] [Abstract][Full Text] [Related]
18. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
Karpf AR; Moore BC; Ririe TO; Jones DA
Mol Pharmacol; 2001 Apr; 59(4):751-7. PubMed ID: 11259619
[TBL] [Abstract][Full Text] [Related]
19. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines.
Hagemann S; Heil O; Lyko F; Brueckner B
PLoS One; 2011 Mar; 6(3):e17388. PubMed ID: 21408221
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
